Medical bibliography. UV phototherapy for psoriasis, vitiligo, dermatitis, hyperhidrosis,
acne and laser therapy for hair loss.

Main Categories:

Sub Categories:

Popular Products:

 
Dermaray UV phototherapy wand.
Dermaray UV treatment
 
Dermaray Laser Comb.
Dermaray Laser Comb
 
 
natural treatment packs
Natural treatment products
 
Psoriasis Diet.
Psoriasis diet
 
 
 

Bibliography of our source material

Here you will find our general frequently asked questions. If your question is not answered here, please feel free to contact us.

Return to the FAQs index

1. Vitiligo bibliography and references

2. Psoriasis bibliography and references

3. Acne bibliography and references

 

1. Vitiligo bibliography and references

AHMED, S. (1998) ‘Animated Borders: Skin, Colour and Tanning', in Shildrick, M. and Price, J. (eds.) Vital Signs, Texts, Borders and Biomedicine , Edinburgh : Edinburgh University Press.
BBC RADIO 4 (2002) ‘Skin Deep' 13 October 2002 , 13.30-14.00pm .
BRYMAN, A. (2001) Social Research Methods , Oxford : Oxford University Press.
BULL, R. and DAVID, I. (1986) ‘The Stigmatising Effect of Facial Disfigurement', Journal of Cross-Cultural Psychology , vol. 17, no. 1, pp. 99-108.
ELLIS, C. (1998) ‘ “I Hate My Voice”: Coming to Terms with Minor Bodily Stigmas', The Sociological Quarterly , vol. 39, no. 4, pp. 517-537.
FINALY, A. Y. and COLES, E. C. (1995) ‘The Effect of Severe Psoriasis on the Quality of Life of 369 Patients', British Journal of Dermatology , vol. 132, pp. 236-244.
GARDENER, C. B. (1991) ‘Stigma and the Public Self: Notes on Communication, Self and Others', Journal of Contemporary Ethnography , vol. 20, no. 3, pp. 251-262.
GOFFMAN, E. (1963) Stigma: Notes on the Management of Spoiled Identity , London : Prentice-Hall Press.
GUARDIAN (1997) ‘Losing Face: Janet Haslam on the Skin Disease which Causes Gradual Loss of Colour' 2 December 1997 , p. 16.
HAWKESWORTH, M. (2001) ‘Disabling Spatialities and the Regulation of a Visible Secret', Urban Studies , vol. 38, no. 2, pp. 299-318.
JACOBY, A. (1998) ‘Felt Versus Enacted Stigma: A Concept Revisited', Social Science and Medicine , vol. 38, no. 2, pp. 269-274.
KENT , G. (1999) ‘Correlates of Perceived Stigma in Vitiligo', Psychology and Health , vol. 15, pp. 241-251.
KENT, G. (2000) ‘Understanding the Experiences of People with Disfigurement: An Integration of Four Models of Social and Psychological Functioning', Psychology, Health and Medicine , vol. 5, no. 2, pp. 117-129
LEE-TREWEEK, G. and LINKGOLE, S. (eds.) (2000) Danger in the Field: Risk and Ethics in Social Research , London : Routledge.
LESAGE, M. (2002) Vitiligo: Understanding the Loss of Skin Colour , second edition, London : The Vitiligo Society.
MAGIONE, T. W. (1995) Mail Surveys: Improving the Quality , Thousand Oaks , California : Sage Publications.
MONTAGU, A. (1971) Touching: The Human Significance of the Skin , London : Columbia University Press.
NEW YORK TIMES (2003) ‘A Guide to Skin Disease Through the Eyes of a Boy' 15 July 2003 , p. F7, col. 5.
OBSERVER (2002) ‘Ebony and Ivory' 10 November 2002 , p. 23.
PORTER, J. R. and BEUF, A. H. (1988) ‘Response of Older People to Impaired Appearance: The Effect of Age on Disturbance of Vitiligo', Journal of Ageing Studies , vol. 2, no. 2, pp. 167-181.
PORTER, J. R. et. al. (1990) ‘The Effect of Vitiligo on Sexual Relationships', Journal of the American Academy of Dermatology , vol. 22, pp. 221-222.
PORTER, J. R. and BEUF, A. H. (1991) ‘Racial Variation in Reaction to Physical Stigma: A Study of Degree of Disturbance by Vitiligo Among Black and White Patients', Journal of Health and Social Behaviour , vol. 32, no. 2, pp. 192-204.
ROSENBERG , M. (1965) Society and the Adolescent Self-Image , Princeton , New Jersey : Princeton University Press.
SCAMBLER, G. AND HOPKINS, A. (1980) ‘Being Epileptic: Coming to Terms with Stigma', Sociology of Health and Illness , vol. 8, pp. 26-45.
WILLIAMS, J. I. (1971) ‘Disease as Deviance', Social Science and Medicine , vol. 5, pp. 219-226.

[top of page]

 

2. Psoriasis bibliography and references

Bowcock AM: Genetic locus for psoriasis identified. Ann Med 1995 Apr; 27(2): 183-6[Medline].
Cullar ML, Espinoza LR: Psoriatic arthritis: Current developments. J Fla Med Assoc 1995; 82 (5): 338-42.
Elder JT, Henseler T, Christophers E, et al: Of genes and antigens: the inheritance of psoriasis. J Invest Dermatol 1994 Nov; 103(5 Suppl): 150S-153S[Medline].
Farber EM, Nall L: Psoriasis. A review of recent advances in treatment. Drugs 1984 Oct; 28(4): 324-46[Medline].
Farber EM: Therapeutic perspectives in psoriasis. Int J Dermatol 1995 Jul; 34(7): 456-60[Medline].
Greaves MW, Weinstein GD: Treatment of psoriasis. N Engl J Med 1995 Mar 2; 332(9): 581-8[Medline].
Lebwohl MG: The evolution of vitamin D analogues for the treatment of psoriasis. Arch Dermatol 1995 Nov; 131(11): 1323-4[Medline].
Lewis HM: Therapeutic progress. II: Treatment of psoriasis. J Clin Pharm Ther 1994 Aug; 19(4): 223-32[Medline].
Naldi L: Psoriasis. Dermatol Clin 1995 Jul; 13(3): 635-47[Medline].
Pines A, Ehrenfeld M, Fisman EZ, et al: Mitral valve prolapse in psoriatic arthritis. Arch Intern Med 1986 Jul; 146(7): 1371-3[Medline].
Raychaudhuri SP, Rein G, Farber EM: Neuropathogenesis and neuropharmacology of psoriasis. Int J Dermatol 1995 Oct; 34(10): 685-93[Medline].
Task Force on Psoriasis: Guidelines of care for psoriasis. Committee on Guidelines of Care. Task Force on Psoriasis. J Am Acad Dermatol 1993 Apr; 28(4): 632-7[Medline].
Valdimarsson H, Sigmundsdottir H, Jonsdottir I: Is psoriasis induced by streptococcal superantigens and maintained by M- protein-specific T cells that cross-react with keratin? Clin Exp Immunol 1997 Jan; 107 Suppl 1: 21-4[Medline].
Weinstein, GD: Tazarotene: A novel retinoid for the topical treatment of psoriasis. Pharmacy and Therapeutics 1997; August: 377-81.

Charmaz K. Good Days, Bad Days: The Self in Chronic Illness and Time. New Brunswick, NJ: Rutgers University Press; 1993.

Cram DL. Coping With Psoriasis: A Patient's Guide to Treatment. Omaha, Neb: Addicus Books; 2000.

Derzaph ED. Psoriasis: The Struggle and the Triumph—A Healthy Transformation for Everyone Living With Psoriasis. Bloomington, Ind: 1stBooks Library; 2003.

Dewke ES. Flake: Confessions of a Psoriatic. Lexington, Ky: BGC Books; 1996.

Grossbart TA, Sherman C. Skin Deep: A Mind/Body Program for Healthy Skin. Rev ed. Santa Fe, NM: Health Press; 1992.

LeVan L. The Psoriasis Cure. Garden City Park, NY: Avery Publishing Group; 1999.

Lowe NJ. Managing Your Psoriasis. New York, NY: Mastermedia; 1993.

National Psoriasis Foundation. The Best of It Works For Me: 1991–1999. Portland, Ore: National Psoriasis Foundation; 2000.

Pitzele SK. We Are Not Alone: Learning to Live With Chronic Illness. New York, NY: Workman Publishing; 1986.

Abell E. Treatment of psoriatic nail dystrophy. Br J Dermatol 1972;86:79-82.

duVivier A, Stoughton RB. Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol 1975;111:581-3.

Katz HI, Hien HT, Prawer SE, et al. Superpotent topical steroid treatment of psoriasis vulgaris: clinical efficacy and adrenal function. J AM ACAD DERMATOL 1987;16:804-11.

Lee SS. Topical steroids (review). Int J Dermatol 1981;20:632-41.

Nilsson JE, Gip LJ. Systemic effects of local treatment with high doses of potent corticosteroids in psoriatics. Acta Derm Venereol (Stockh) 1979;59:245-8.

Tan PL, Barnett GL, Flowers FP, et al. Current topical corticosteroid preparations. J AM ACAD DERMATOL 1986;14:79-93.

Vickers CFH. Topical corticosteroids. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al, eds. Dermatology in general medicine. 3rd ed. New York: McGraw-Hill, 1987:2540-5.

Chapman RS, Finn OA. An assessment of high and low temperature tars in psoriasis. Br J Dermatol 1976;94:71-4.

Finlay AY, Young DW. Short contact coal tar therapy for psoriasis. Clin Exp Dermatol 1985;10:371-4.

Lavker RM, Grove GL, Kligman AM. The atrophogenic effect of crude coal tar on human epidermis. Br J Dermatol 1981;105:77-82.

Lin AN, Moses K. Tar revisited. Int J Dermatol 1985;24:216-8.

Lowe NJ, Wortzman MS, Breeding J, et al. Coal tar phototherapy for psoriasis reevaluated: erythemogenic versus suberythemogenic ultraviolet with a tar extract in oil and crude coal tar. J AM ACAD DERMATOL 1983;8:781-9.

Petrozzi JW, Barton JO, Kaidbey KH, et al. Updating the Goeckerman regimen for psoriasis. Br J Dermatol 1978;98:437-44.

Stern RS, Gange RW, Parrish JA, et al. Contribution of topical tar oil to ultraviolet B phototherapy for psoriasis. J AM ACAD DERMATOL 1986;14:742-7.

Young E. The external treatment of psoriasis: a controlled investigation of the effects of coal tar. Br J Dermatol 1970;82:510-5.

Abel EA, O’Connell BM, Farber EM. Psoriasis day care center at Stanford: part-time and full-time programs. Int J Dermatol 1987;26:500-7.

Ashton RE, Andre P, Lowe NJ, et al. Anthralin: historical and current perspectives. J AM ACAD DERMATOL 1983;9:173-92.

Ingram JT. The approach to psoriasis. Br Med J 1953;591-4.

Lowe NJ, Ashton RE, Koudsi H, et al. Anthralin for psoriasis: short-contact anthralin therapy compared with topical steroid and conventional anthralin. J AM ACAD DERMATOL 1984;10:69-72.

Ryatt KS, Statham BN, Rowell NR. Short-contact modification of the Ingram regimen. Br J Dermatol 1984;111:455-9.

Davies MG, Briffa DV, Greeves MW. Systemic toxicity from topically applied salicylic acid. Br Med J 1979;1:661.

Going SM, Guyer BM, Jarvie DR, et al. Salicylic acid gel for scalp psoriasis. Clin Exp Dermatol 1986;11:260-2.

Goldsmith LA. Salicylic acid. Int J Dermatol 1979;18:32-6.

Hulsebosch HJ, Ponec-Waelsch M. The interaction of anthralin, salicylic acid and zinc oxide in pastes. Dermatologica 1972;144:287-93.

Van Scott EJ, Yu RJ. Alpha hydroxy acids: procedures for use in clinical practice. Cutis 1989;43:222-8.

Van Scott EJ, Yu RJ. Control of keratinization with L-hydroxy acids and related compounds. Arch Dermatol 1974;110:586-90.

Rosenberg EW, Noah PW, Zanolli MD, et al. Use of rifampin with penicillin and erythromycin in the treatment of psoriasis. J AM ACAD DERMATOL 1986;14:701-4.

Rosenberg EW, Skinner RB, Noah PW. Antimicrobial treatment of psoriasis. In: Roenigk HH, Maibach HI, eds. Psoriasis. 2nd ed. revised and expanded. New York: Marcel Dekker, 1991:815-22.

Tefler NR, Chalmers RJG, Wale K, et al. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol 1992;128:39-42.

Whyte HS, Baughman RD. Acute guttate psoriasis and streptococcal infection. Arch Dermatol 1964;89:350-6.

Ashton RE, Millward-Sadler GH, White JE. Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis. J Invest Dermatol 1982;79-229-32.

Dahl MGC. Methotrexate and the liver. Br J Dermatol 1969;81:465-7.

Hanno R, Gruber GG, Owen LG, et al. Methotrexate in psoriasis. J AM ACAD DERMATOL 1980;2:171-4.

Jolivet J, Cowan KH, Curg GA, et al. The pharmacology and clinical use of methotrexate. N Engl J Med 1983;309:1094-104.

Reese LT, Grisham JW, Aach RD, et al. Effects of methotrexate on the liver in psoriasis. J Invest Dermatol 1974;62:597-602.

Roenigk HH, Auerbach R, Maibach HI, et al. Methotrexate in psoriasis: revised guidelines. J AM ACAD DERMATOL 1988;19:145-56.

Weinstein GD. Methotrexate. Ann Intern Med 1977;86:199-204.

Zachariae H, Kragballe K, Søgaard H. Methotrexate-induced liver cirrhosis. Br J Dermatol 1980;102:407-12.

Leavell UW, Mersack IP, Smith C. Survey of the treatment of psoriasis with hydroxyurea. Arch Dermatol 1973;107:467.

McDonald CJ. Chemotherapy of psoriasis. Int J Dermatol 1975;14:563-74.

Moschella SL. Chemotherapy of psoriasis: ten years of experience.. Int J Dermatol 1976;15:373-8.

Moschella SL, Greenwald MA. Psoriasis with hydroxyurea: an eighteen month study of sixty patients. Arch Dermatol 1973;107:363-8.

Roe LD, Wilson JW. Hydroxyurea therapy. Arch Dermatol 1973;108:426-7.

Rosten M. Hydroxyurea: a new antimetabolite in the treatment of psoriasis. Br J Dermatol 1971;85:177-81.

Ellis CN, Hermann RC, Gorsulowsky DC, et al. Etretinate therapy reduces inpatient treatment of psoriasis. J AM ACAD DERMATOL 1987;17:787-91.

Ellis CN, Swanson NA, Grekin RC, et al. Etretinate therapy causes increases in lipid levels in patients with psoriasis. Arch Dermatol 1982;118:559-62.

Ellis CN, Voorhees JJ. Etretinate therapy. J AM ACAD DERMATOL 1987;16:267-91.

Goldfarb MT, Ellis CN, Gupta AK, et al. Acitretin improves psoriasis in a dose-dependent fashion. J AM ACAD DERMATOL 1988;18:655-62.

Goldfarb MT, Ellis CN, Voorhees JJ. Short-term and long-term considerations in the management of psoriasis with retinoids. Dermatologica 1987;175:100-6.

Kaplan RP, Russell DH, Lowe NJ. Etretinate therapy for psoriasis: clinical responses, remission times, epidermal DNA and polyamine responses. J AM ACAD DERMATOL 1983;8:95-102.

Lowe NJ, Lazarus V, Matt L. Systemic retinoid therapy for psoriasis. J AM ACAD DERMATOL 1988;19:186-91.

Roenigk HH, Gibstine C, Glazer S, et al. Serial liver biopsies in psoriatic patients receiving long-term etretinate. Br J Dermatol 1985;112:77-81.

Silverman AK, Ellis CN, Voorhees JJ. Hypervitaminosis A syndrome: a paradigm of retinoid side effects. J AM ACAD DERMATOL 1987;16:1027-39.

White SI, Marks JM, Shuster S. Etretinate in pustular psoriasis of palms and soles. Br J Dermatol 1985;113:581-5.

Wolska H, Jablonska S, Bounameaux Y. Etretinate in severe psoriasis. J AM ACAD DERMATOL 1983;9:883-9.

Fergusson AG, Dwar WA. Observations on steroid therapy in psoriasis. Br J Dermatol 1957;69:57-60.

Goodwin P. The effect of corticosteroids on cell turnover in the psoriatic patient: a review. Br J Dermatol 1976;94:95-100.

Mikhail GR, Livingood CS, Mellinger RC, et al. Effect of long-acting parental corticosteroids on adrenal function. Arch Dermatol 1969;100:263-8.

Storrs FJ. Use and abuse of systemic corticosteroid therapy. J AM ACAD DERMATOL 1979;1:95-105.

Adrian RM, Parrish JA, Momtaz TK, et al. Outpatient phototherapy for psoriasis. Arch Dermatol 1981;117:623-6.

Diffey BL, Farr PM. An appraisal of ultraviolet lamps used for the phototherapy of psoriasis. Br J Dermatol 1987;117:49-56.

Levine MJ, Parrish JA. Outpatient phototherapy of psoriasis. Arch Dermatol 1980;116:552-4.

Parrish JA. Photobiologic principles of phototherapy and photochemotherapy of psoriasis. Pharmacol Ther 1981;15:439-46.

Parrish JA. Ultraviolet phototherapy of psoriasis. Pharmacol Ther 1981;15:313-20.

Stern RS, Armstrong RB, Anderson TF, et al. Effect of continued ultraviolet B phototherapy on the duration of remission of psoriasis: a randomized study. J AM ACAD DERMATOL 1986;15:546-52.

Farber EM, Abel EA, Cox AJ. Long-term risks of psoralen and UV-A therapy for psoriasis. Arch Dermatol 1983;119:426-31.

Lowe NJ, Weingarten D, Bourget T, et al. PUVA therapy for psoriasis: comparison of oral and bath-water delivery of 8-methoxypsoralen. J AM ACAD DERMATOL 1986;14:754-60.

McEvoy MT, Stern RS. Psoralens and related compounds in the treatment of psoriasis. Pharmacol Ther 1987;34:75-97.

Melski J, Tanenbaum, L, Parrish JA, et al. Oral methoxsalen photochemotherapy for treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol 1977;68:328-35.

Morison WL. PUVA combination therapy. Photodermatology 1985;2:229-36.

Parrish JA, Fitzpatrick TB, Tanenbaum L, et al. Photochemotherapy of psoriasis with oral methoxsalen and long-wave ultraviolet light. N Engl J Med 1974;291:1207-11.

Parrish JA, LeVine MJ, Fitzpatrick TB. Oral methoxsalen photochemotherapy of psoriasis and mycosis fungoides. Int J Dermatol 1980;19:379-86.

Stern RS, Thibodeau LA, Kleinerman RA, et al. Risk of cutaneous carcinoma in patients treated with oral methoxsalen photochemotherapy for psoriasis. N Engl J Med 1979;300:809-13.

Bohm ML, Voorhees JJ. The role of the ambulatory psoriasis treatment center as a cost-effective program for severe psoriasis. J AM ACAD DERMATOL 1985;12:740-7.

Bohm ML, Voorhees JJ. White paper on hospitalization for psoriasis care. J AM ACAD DERMATOL 1984;10:842-51.

Menter A, Cram DL. The Goeckerman regimen in two psoriasis day care centers. J AM ACAD DERMATOL 1983;9:59-65.

Menter MA, Whiting DA, McWilliams J. Resistant childhood psoriasis: an analysis of patients seen in a day car center. Pediatr Dermatol 1984;2:8-12.

Muller SA, Perry HO. The Goeckerman treatment in psoriasis: six decades of experience at the Mayo Clinic. Cutis 1984;34:265-8, 270.

Perry HO, Soderstrom CW, Schulze TW. The Goeckerman treatment of psoriasis. Arch Dermatol 1968;98:178-82.

Pittelkow MR, Perry HO, Muller SA, et al. Skin cancer in patients with psoriasis treated with coal tar: a 25-year follow-up study. Arch Dermatol 1981;117:465-8.

Fritsch P, Honigsmann H, Jaschke E, et al. Augmentation of oral methoxsalen-photochemotherapy with an oral retinoic acid derivative. J Invest Dermatol 1978;70-178-82.

Michaelsson G, Noren P, Vahlquist A. Combined therapy with oral retinoid and PUVA baths in severe psoriasis. Br J Dermatol 1978;99:221-2.

Van de Kerkhof PCM, Volden G, Gollnick H. Comparisons and combinations. In: Mier P, Van de Kerkhof PCM, eds. Textbook of psoriasis. New York: Churchill-Livingstone, 1986:268-77

Stern RS. Utilization of outpatient care for psoriasis. J Am Acad Dermatol. 1996;35:543-545.

Nanda A, Kaur S, Kaur I, Kumar B. Childhood psoriasis: an epidemiologic survey of 112 patients. Pediatr Dermatol. 1990;7:19-21.

Leung DY, Travers JB, Giorno R, et al. Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J Clin Invest. 1995;96:2106-2112.

Ryan TJ, Baker H. The prognosis of generalized pustular psoriasis. Br J Dermatol. 1971;85:407-411.

Ohkawara A, Yasuda H, Kobayashi H, et al. Generalized pustular psoriasis in Japan: two distinct groups formed by differences in symptoms and genetic background. Acta Derm Venereol. 1996;76:68-71.

Boyd AS, Menter A. Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol. 1989;21:985-991.

Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol. 2001;45:487-498.

Honigsmann H. Phototherapy for psoriasis. Clin Exp Dermatol. 2001;26:343-350.

arrish JA, Jaenicke KF. Action spectrum for phototherapy of psoriasis. J Invest Dermatol. 1981;76:359-362.

Shelk J, Morgan P. Narrow-band UVB: a practical approach. Dermatol Nurs. 2000;12:407-411.

Spann CT, Barbagallo J, Weinberg JM. A review of the 308-nm excimer laser in the treatment of psoriasis. Cutis. 2001;68:351-352.

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210-216.

Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol. 2000;43:281-285.

Parrish JA, Fitzpatrick TB, Tanenbaum L, Pathak MA. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med. 1974;291:1207-1211.

Helm TN, Camisa C. "Psoralens and photochemotherapy (PUVA)". In: Handbook of Psoriasis, ed.2, Camisa C (ed), 2004, Blackwell, Oxford, UK, pp.191-214.

Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol. 2001;45:649-661.

Roenigk HH Jr, Bergfeld WF, Curtis GH. Methotrexate for psoriasis in weekly oral doses. Arch Dermatol. 1969;99:86-93.

Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003; 349:658-665.

Roenigk HH Jr, Auerbach R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol. 1998;38:478-485.

Lebwohl M, Ellis C, Gottlieb A, Koo J, Krueger G, Linden K, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol. 1998;39:464-475.

van De Kerkhof PC. New developments in the treatment of psoriasis. Skin Pharmacol Appl Skin Physiol. 2001;14:129-135.

Kumar B, Saraswat A, Kaur I. Rediscovering hydroxyurea: its role in recalcitrant psoriasis. Int J Dermatol. 2001;40:530-534.

Duvivier A, Munro DD, Verbov J. Treatment of psoriasis with azathioprine. Br Med J. 1974;1:49-51.

Silvis NG, Levine N. Pulse dosing of thioguanine in recalcitrant psoriasis. Arch Dermatol. 1999;135:433-437.

Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol. 1987;17:962-971.

Ameen M, Smith HR, Barker JN. Combined mycophenolate mofetil and cyclosporine therapy for severe recalcitrant psoriasis. Clin Exp Dermatol. 2001;26:480-483.

Gupta AK, Ellis CN, Seigel MT, et al. Sulfasalazine improves psoriasis. A double-blind analysis. Arch Dermatol. 1990;126:487-493.

Combe B, Gouipille P, Kuntz JL, et al. Sulfasalazine in psoriaitic arthritis: a randomized, multi-centre, placebo-controlled study. Br J Rheumatol. 1996;35:664-668.

European FK 506 Multi-centre psoriasis study group. Systemic tacrolimus (FK-506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol. 1996;132:419-423.

Rappersberger K, Komar M, Ebelin ME, et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol. 119;876-887, 2002.

Granstein RD. New treatments for psoriasis. N Engl J Med. 2001;345:284-287.

Ellis CN, Krueger GG. Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001;345:248-255.

Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004-2013.

Leonardi C, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-2022.

Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51:534-42.

Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis. 2001;68:355-358. [top of page]

 

3. Acne bibliography and references

Fulton JE Jr, Plewig G, Kligman AM. Effect of chocolate on acne vulgaris. JAMA 1969;210:2071–74
Anderson PC. Foods as the cause of acne. Am Family Phys 1971;3:102–3.
Gaby A. Commentary. Nutr Healing Feb 1997;1,10,11.
Hillstrom L et al. Comparison of oral treatment with zinc sulfate and placebo in acne vulgaris. Br J Dermatol 1977;97:679–84.
Michaelsson G et al. A double blind study of the effect of zinc and oxytetracycline in acne vulgaris. Br J Dermatol 1977;97:561–66.
Kligman AM et al. Oral vitamin A in acne vulgaris. Int J Dermatol 1981;20:278–85.
Snider B, Dietman DF. Pyridoxine therapy for premenstrual acne flare. Arch Dermatol 1974;110:130–31.
Leung LH. Pantothenic acid deficiency as the pathogenesis of acne vulgaris. Med Hypoth 1995;44:490–92.
Shality AR, Smith JR, Parish LC, et al. Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. Internat Dermatol 1995;34:434–37.
Bassett IB, Pannowitz DL, Barnetson RS. A comparative study of tea-tree oil versus benzoyl peroxide in the treatment of acne. Med J Austral 1990;53:455–58.
Hoffman D. The Herbal Handbook: A User’s Guide to Medical Herbalism. Rochester, VT: Healing Arts Press, 1988, 23–24.
Amann W. Improvement of acne vulgaris with Agnus castus (Agnolyt ™). Ther Gegenw. 1967;106:124–26 [in German].
Birnkrant MJ, Papadopoulos AJ, Schwartz RA, Lambert WC: Pyoderma gangrenosum, acne conglobata, and IgA gammopathy. Int J Dermatol 2003 Mar; 42(3): 213-6[Medline].
Champion RH, Burton JL, Burns DA, Breathnach SM, eds: Rook/Wilkinson/Ebling Textbook of Dermatology. 6th ed. Oxford: Blackwell Science; 1998:1967,1979.
Cunliffe WJ: Acne. 3rd ed. Martin Dunitz Publishers; 1993.
Ehrenfeld M, Samra Y, Kaplinsky N: Acne conglobata and arthritis: report of a case and review of the literature. Clin Rheumatol 1986 Sep; 5(3): 407-9[Medline].
el-Shahawy MA, Gadallah MF, Massry SG: Acne: a potential side effect of cyclosporine A therapy. Nephron 1996; 72(4): 679-82[Medline].
Ena P, Zanetti S, Sechi LA: Mycobacterium chelonae I infection mimicking acne conglobata in an immunocompetent host. Clin Exp Dermatol 2004 Jul; 29(4): 423-5[Medline].
Jansen T, Burgdorf WH, Plewig G: Pathogenesis and treatment of acne in childhood. Pediatr Dermatol 1997 Jan-Feb; 14(1): 17-21[Medline].
Jeong S, Lee CW: Acne conglobata: treatment with isotretinoin, colchicine, and cyclosporin as compared with surgical intervention. Clin Exp Dermatol 1996 Nov; 21(6): 462-3[Medline].
Leybishkis B, Fasseas P, Ryan KF, Roy R: Hidradenitis suppurativa and acne conglobata associated with spondyloarthropathy. Am J Med Sci 2001 Mar; 321(3): 195-7[Medline].
Leyden JJ, Mills OH, Kligman AM: Cryoprobe treatment of acne conglobata. Br J Dermatol 1974 Mar; 90(3): 335-41[Medline].
Patterson WM, Stibich AS, Dobke M, Schwartz RA: Mutilating facial acne conglobata. Cutis 2000 Aug; 66(2): 139-40[Medline].
Perez-Villa F, Campistol JM, Ferrando J, Botey A: Renal amyloidosis secondary to acne conglobata. Int J Dermatol 1989 Mar; 28(2): 132-3[Medline].
Plewig G, Kligman AM: Acne and Rosacea . Berlin: Springer-Verlag; 1993:351-5.
Roldan JC, Terheyden H, Dunsche A, et al: Acne with chronic recurrent multifocal osteomyelitis involving the mandible as part of the SAPHO syndrome: case report. Br J Oral Maxillofac Surg 2001 Apr; 39(2): 141-4[Medline].
Schackert K, Scholz S, Steinbauer-Rosenthal I, et al: Letter: HL-A antigens in acne conglobata: a negative study. Arch Dermatol 1974 Sep; 110(3): 468[Medline].
Shimomura Y, Nomoto S, Yamada S, et al: Chronic glomerulonephritis remarkably improved after surgery for acne conglobata of the buttocks. Br J Dermatol 2001 Aug; 145(2): 363-4[Medline].
Tan BB, Lear JT, Smith AG: Acne fulminans and erythema nodosum during isotretinoin therapy responding to dapsone. Clin Exp Dermatol 1997 Jan; 22(1): 26-7[Medline].
Vasey FB, Fenske NA, Clement GB, et al: Immunological studies of the arthritis of acne conglobata and hidradenitis suppurativa. Clin Exp Rheumatol 1984 Oct-Dec; 2(4): 309-11[Medline].
Velez A, Alcala J, Fernandez-Roldan JC: Pyoderma gangrenosum associated with acne conglobata. Clin Exp Dermatol 1995 Nov; 20(6): 496-8[Medline].
Weinrauch L, Peled I, Hacham-Zadeh S, Wexler MR: Surgical treatment of severe acne conglobata. J Dermatol Surg Oncol 1981 Jun; 7(6): 492-4[Medline].
Wollenberg A, Wolff H, Jansen T, et al: Acne conglobata and Klinefelter's syndrome. Br J Dermatol 1997 Mar; 136(3): 421-3[Medline].
Yeon HB, Lindor NM, Seidman JG, Seidman CE: Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome maps to chromosome 15q. Am J Hum Genet 2000 Apr; 66(4): 1443-8[Medline].
Zaba R: Pathogenesis and treatment of acne vulgaris. Postepy Dermatol Alergol (Postepy) 2001; 18: 131-140.
Ziff M, Maliakkal J: Acne conglobata and arthritis. Ann Intern Med 1983 Mar; 98(3): 417[Medline].

[top of page]

 

Beat Psoriasis on Facebook.

Buy Now

Buy UVB phototherapy without a prescription.

Beatpsoriasis UVB treatment forum.

 

Why Beat Psoriasis?

  • no prescription needed
  • no doctors letter
  • fast worldwide delivery
  • lowest price guarantee
  • easy online ordering
  • highest service levels
  • best quality products
  • secure online ordering

Who are our clients?

  • home & personal users
  • hospitals & clinics
  • dermatologists
  • specialist doctors
  • naturopaths

psoriasis

Psoriasis is a common skin disease that causes raised red skin with thick silvery scales.

vitiligo

Vitiligo is a disorder in which white patches of skin appear on the body

hair loss

Hair loss usually develops gradually and may be patchy or diffuse

acne

Acne is a disorder of the hair follicles and sebaceous oil glands that leads to skin infections

dermatitis

Inflammation of the skin, often a rash, swelling, pain, itching, cracking. Can be caused by an irritant or allergen

frequent questions

 
site footer banner